The event will begin shortly.

*The content of this webinar is intended for information only and is not to be considered legal advice.*

• **Before we begin:**
  • The audio is being streamed through your computer. Please turn your computer speakers on. There is NO call in number.
  • You may need to disable pop-up blocking software in order for the presentation software to properly load.
  • Review our Tech Tips to enhance your viewing experience and troubleshoot common technical issues.
Confluence of a National Epidemic and Global Pandemic

Confronting Pain and Opioid Use Disorders Amid COVID-19

Access to Medication-Assisted Treatment

Monday, July 27, 2020
3:30pm – 4:30pm
Take Control of Your Console

• All open windows can be adjusted.

• Use the controls to minimize or maximize icons:

• Drag the bottom right hand corner to resize your window:
Today's Agenda

1. A View from Capitol Hill: Congressional Response to MAT Access
   The Honorable Paul Tonko (NY-20), United States House of Representatives

2. Targeting Policy Changes to Impact Treatment Access and Availability
   Claire Brennan, Section Chief, Liaison Section, Diversion Control Division, DEA
   Anastasia Martin, Staff Coordinator, Policy Section, Diversion Control Division, DEA

3. Panel Discussion and Roundtable: Leveraging Technology and Innovation to Drive Evidence-Based Care
   a. Sam Arsenault, MA, Vice President, National Treatment Quality Initiatives, Shatterproof
   b. Yuri Maricich, MD, MBA, Chief Medical Officer, Pear Therapeutics
   c. Mark Parrino, MPA, President, American Association for the Treatment of Opioid Dependence (AATOD)

Mr. Van Ingram
Executive Director
Kentucky Office of Drug Control Policy
A View from Capitol Hill – Congressional Response to Addiction Treatment During COVID-19

The Honorable Paul Tonko

U.S. House of Representatives
House Committee on Energy & Commerce
DEA’s Response to COVID-19

DIVERSION CONTROL DIVISION
LIAISON SECTION CHIEF CLAIRE BRENNAN
DEA POLICY SECTION STAFF COORDINATOR ANASTASIA MARTIN
Drug Enforcement Administration Diversion Control Division

Responsibilities:

- **Schedule** controlled substances
- **Set** production quotas
- **Establish** import and export controls
- **Investigate** DEA registrants to detect diversion
- **Conduct** liaison with industries and associations representing registrants
- **Assist** state and local authorities
- **Represent** the United States on matters related to controlled substances and regulated chemicals at the United Nations
- **Responsible** for drafting and publishing regulations
Executive Order 13891
November 1, 2019

➢ Requires DEA to obtain permission from the Department of Justice (DOJ) and the Office of Management and Budget (OMB) prior to publishing any public guidance document.

➢ Prior to this Executive Order DEA could publish guidance documents on their own.
Drug Enforcement Administration
Timeline of COVID-19 Response

January 27, 2020
Secretary of Health and Human Services (HHS) declares the coronavirus a public health threat

January 31, 2020
HHS declares a Public Health Emergency

March 15 – April 20
DEA issues 24 emergency guidance documents to assist practitioners in the treatment of patients
Medication Assisted Treatment Guidance During COVID-19

- Exemption Allowing Alternate Delivery Methods for OTPs - March 16, 2020
- Use of Telephone Evaluations to Initiate Buprenorphine Prescribing - March 31, 2020
- Use of Unregistered Off-Site Locations in MAT - April 7, 2020
- Distributor shipments to NTP's signed delivery exception - April 11, 2020
- Use of Unregistered Off-Site Locations in MAT (Buprenorphine) - April 28, 2020
Drug Enforcement Administration
Guidance During COVID-19

- Suspicious Orders & Due Diligence
- Prescriptions
- Registration
- Quota
- National Drug Supply
- Electronic Prescribing of Controlled Substances
- Telemedicine
- Records and Reports
Drug Enforcement Administration
Prescription Medication Take Back

TakeBackDay.DEA.gov
Leveraging Technology and Innovation to Drive Evidence-Based Care

Cataloging the Impacts of COVID-19 on SUD Treatment Access and Related Policy Interventions
Meet Your Panelists

**Samantha Arsenault, MA**
Vice President, National Treatment Quality Initiatives, Shatterproof

**Yuri Maricich, MD, MBA**
Chief Medical Officer, Pear Therapeutics

**Mark Parrino, MPA**
President, American Association for the Treatment of Opioid Dependence (AATOD)
Roundtable Question & Answer Session

Please submit questions to our panelists using the chat function in the left-hand side of your screen.

If joining via mobile device, email questions to matthew.rubin@faegredrinker.com.
Upcoming CEPOP-MAPDA Webinars

- **Digital Health and Telemedicine**
  - Monday, July 20 at 3:00 p.m. ET

- **Policy Changes to Medication-Assisted Treatment**
  - Monday, July 27 at 3:30 p.m. ET

- **Access and Utilization of Overdose Reversal Medications**
  - Monday, August 10 at 3:00 p.m. ET

- **Excess Medications in the Home**
  - Monday, August 17 at 3:00 p.m. ET
Thank you for joining us today!

Please refer any questions to:
matthew.rubin@faegredrinker.com
+1 202 312 7456